| abstract |
Combination therapies are disclosed, comprising the selective mutated EGFR inhibitor EGF816 and an immunomodulator chosen from one or more of an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule. An example of such an inhibitor of an immune checkpoint molecule is the anti-PD-1 monoclonal antibody Nivolumab. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. |